Illumina (WBO:ILMN) Long-Term Debt: €1,289 Mil (As of Mar. 2026)


WBO:ILMN Illumina Inc WBO:ILMN
67 GF Score
Price €163.26
GF Value €112.52
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Illumina Long-Term Debt?

Illumina WBO:ILMN -2.29% 67 Long-Term Debt is €1,289 Mil as of Mar. 2026. GuruFocus rates WBO:ILMN with a GF Score™ of 67/100 and a GF Value™ of €112.52 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Illumina's Long-Term Debt for the quarter that ended in Mar. 2026 was €1,289 Mil.

Illumina's quarterly Long-Term Debt increased from Sep. 2025 (€847 Mil) to Dec. 2025 (€1,272 Mil) and increased from Dec. 2025 (€1,272 Mil) to Mar. 2026 (€1,289 Mil).

Illumina's annual Long-Term Debt increased from Dec. 2023 (€1,365 Mil) to Dec. 2024 (€1,423 Mil) but then declined from Dec. 2024 (€1,423 Mil) to Dec. 2025 (€1,272 Mil).

Illumina  (WBO:ILMN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Illumina Long-Term Debt Related Terms

Illumina Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Illumina's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina Long-Term Debt Chart

Illumina Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,500.08 1,403.73 1,365.41 1,422.95 1,272.46

Illumina Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,379.18 1,293.56 846.89 1,272.46 1,288.85
WBO:ILMN
67GF Score
Illumina Inc WBO:ILMN
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €1,289 Mil mean?
Illumina (WBO:ILMN) has a Long-Term Debt of €1,289 Mil as of Mar. 2026.
Is Illumina's Long-Term Debt too high?
Illumina's current Long-Term Debt is €1,289 Mil. Overall, Illumina has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Illumina's Long-Term Debt compare to MTD and DGX?
Illumina's Long-Term Debt of €1,289 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Illumina's current Long-Term Debt is €1,289 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Based on GuruFocus' analysis, Illumina (WBO:ILMN) is currently considered Significantly Overvalued. The stock's GF Value™ is €112.52, compared to a current price of €163.26 — trading 45.1% above its estimated fair value. The current Long-Term Debt is €1,289 Mil. Illumina's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Illumina (WBO:ILMN), the current Long-Term Debt is €1,289 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Illumina (WBO:ILMN) Overvalued in 2026?

Based on GuruFocus' analysis, Illumina stock appears to be overvalued. The current stock price of €163.26 is trading 45.1% above its estimated GF Value™ of €112.52. GuruFocus considers Illumina to be Significantly Overvalued.

Key valuation signals for WBO:ILMN:

  • Long-Term Debt: €1,289 Mil
  • GF Value™: €112.52 vs. price of €163.26 (45.1% above fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the WBO:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Illumina Business Description

Address 5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
67GF Score

Get the complete analysis for WBO:ILMN

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€163.26
Price
€112.52
GF Value